Home › Healthcare Monoclonal Antibody Handling Risk Assessment
Healthcare Monoclonal Antibody Handling Risk Assessment — Generated Instantly for £29
Describe the clinical area, the specific monoclonal antibody, and the allergic reaction previously experienced. We generate a fully written, UK-compliant risk assessment for reintroducing healthcare workers to handling, administering and disposing of the substance safely.
Used by NHS trusts, occupational health teams, private hospitals and specialist infusion clinics across the UK
💉 Reintroducing a worker after an allergy-type reaction? Mention the substance and the symptoms experienced — we'll build a phased return plan with enhanced controls, PPE, monitoring and clear escalation steps.
Legal requirements for monoclonal antibody handling
Monoclonal antibodies used in clinical treatment are classified as hazardous medicinal products under the Control of Substances Hazardous to Health Regulations 2002 (COSHH). Regulation 6 requires a suitable and sufficient assessment of the risks created by exposure, and Regulation 7 requires that exposure is prevented or, where not reasonably practicable, adequately controlled. Where a worker has previously experienced an allergy-type reaction, the assessment must specifically address the risk of re-exposure before that worker returns to handling the substance.
Regulation 12 of COSHH requires appropriate health surveillance where employees are exposed to a substance known to cause occupational asthma, dermatitis or sensitisation. In practice, this means the employer must involve occupational health, document the worker's reaction history, and put in place monitoring arrangements — such as scheduled review after re-exposure — before permitting a return to the clinical area.
The Health and Safety at Work etc. Act 1974 and the Management of Health and Safety at Work Regulations 1999 place a general duty on employers to assess and manage risks to employee health, which underpins the requirement for a documented, worker-specific risk assessment. Where the original reaction meets the reporting threshold, the employer also has duties under RIDDOR 2013. Anyrisks assessments are written to satisfy occupational health review and trust governance requirements.
How it works
1. Describe the situation
Tell us the specific monoclonal antibody, the clinical area, the symptoms previously experienced, and the tasks involved (handling, administering, disposing). Mention any occupational health advice already received.
2. Let the app take the strain
Anyrisks produces a fully written, UK-compliant risk assessment referencing COSHH 2002, health surveillance requirements, and a phased reintroduction plan tailored to the clinical setting.
3. Instant download and use
Download as PDF and Word. Share with occupational health, line management and the worker for sign-off, or file it as part of the trust's governance records. £29, no subscription.
What it covers
Every assessment is written in full — covering the specific reintroduction scenario and all relevant clinical and occupational health controls.
Identification of the specific monoclonal antibody and route of exposure
Review of the previous allergy-type reaction and its severity
COSHH 2002 assessment of risk from re-exposure
Occupational health referral and sign-off requirements
Health surveillance and post-exposure monitoring schedule
Phased reintroduction plan with defined review points
PPE requirements — gloves, gowns, eye and respiratory protection
Safe handling, reconstitution and administration procedures
Sharps and infusion equipment disposal controls
Emergency response plan for anaphylaxis or acute reaction
Escalation and reporting procedures if symptoms recur
RIDDOR 2013 reporting considerations where applicable
Communication plan with line manager, occupational health and the worker
Hazardous pharmaceutical waste disposal compliance
Works for
From oncology day units to rheumatology infusion clinics, Anyrisks covers every clinical setting where monoclonal antibodies are handled.
What customers say
"One of our infusion nurses developed a skin reaction to a biologic and needed a documented reintroduction plan before returning to the unit. Anyrisks gave occupational health exactly the structure they needed to sign it off."
Fiona R.
Occupational health nurse, NHS trust, Yorkshire
"We deal with allergic reactions to biologics more often than people realise. This tool produced a proper COSHH-referenced assessment with a phased return plan in minutes rather than us drafting one from scratch."
Dr Aisha K.
Consultant rheumatologist, private hospital, London
"Our infusion unit needed a clear governance document for a staff member returning after an anaphylaxis scare. It covered monitoring, PPE and escalation, and our clinical governance team approved it straight away."
Tom D.
Clinical services manager, oncology day unit, Manchester
Anyrisks vs DIY templates
| Anyrisks | DIY / Templates | |
|---|---|---|
| Written in full — not a blank form | ✓ | ✗ |
| COSHH 2002 referenced with correct regulation numbers | ✓ | ✗ |
| Tailored to a specific worker's reaction history | ✓ | ✗ |
| Phased reintroduction plan included | ✓ | ✗ |
| Health surveillance and monitoring schedule included | ✓ | ✗ |
| Emergency response plan for acute reaction included | ✓ | ✗ |
| Ready in under 2 minutes | ✓ | ✗ |
| Instant PDF and Word download | ✓ | Sometimes |
Frequently asked questions
Does this cover reintroducing a worker who has had an allergic reaction to a specific monoclonal antibody?
Yes — describe the specific drug (for example rituximab, infliximab, adalimumab or similar), the symptoms experienced (skin reaction, respiratory symptoms, anaphylaxis), and the clinical area. The assessment will cover a phased reintroduction plan with controls, monitoring, and reporting under COSHH 2002 and RIDDOR 2013.
Is this compliant with COSHH 2002 for hazardous medicinal products?
Yes — monoclonal antibodies and other hazardous medicinal products fall under the Control of Substances Hazardous to Health Regulations 2002 (COSHH). The assessment references Regulation 6 (assessment of risk), Regulation 7 (prevention or control of exposure) and Regulation 12 (health surveillance) as appropriate.
Does it address needlestick and sharps injury risk during administration?
Yes — if the monoclonal antibody is administered by infusion or injection, sharps handling and disposal controls are included in line with the Health and Safety (Sharp Instruments in Healthcare) Regulations 2013.
Can this be used for care of employees with sensitisation or occupational allergy?
Yes — this is precisely the scenario the assessment is designed for. It documents the identified hazard, the exposure history, the control measures being introduced, and the ongoing health surveillance and monitoring arrangements required before the worker resumes contact with the substance.
Does it cover disposal of cytotoxic and hazardous pharmaceutical waste?
Yes — disposal procedures for monoclonal antibody vials, giving sets, PPE and sharps are covered, referencing the Hazardous Waste (England and Wales) Regulations 2005 and local trust waste segregation policy.
Is RIDDOR reporting addressed if the allergic reaction was work-related?
Yes — where the original allergic reaction meets the threshold for a reportable disease or dangerous occurrence, the assessment notes the employer's duty to report under the Reporting of Injuries, Diseases and Dangerous Occurrences Regulations 2013 (RIDDOR).
Does it include PPE and respiratory protection requirements?
Yes — recommended PPE (gloves, gowns, eye protection and, where indicated, respiratory protection) is included based on the route of exposure and the reaction previously experienced by the worker.
How quickly can I generate this assessment?
Under 2 minutes. Describe the substance, the clinical area, the worker's reaction history and the reintroduction plan, and Anyrisks produces a complete, regulation-referenced risk assessment instantly, ready for occupational health sign-off.
Also see: The Ultimate Guide to Risk Assessment · Do I Need a Risk Assessment · Risk Assessment Legal Requirements · Risk Assessment Generator